*Purpose: QSant™, an urine-based test was recently introduced for detection of kidney transplant rejection. The test is being utilized at our center to help identify patients at high risk of rejection and for cause indication as well. The purpose of our study was to evaluate any difference in renal function over time in kidney transplant recipients stratified by Qsant scores.

*Methods: Kidney transplant recipients who had been transplanted for at least 6 months were included in the study. The patient’s 3-month serum creatinine was used as the baseline for renal function (Cr3mo) and the most recent creatinine (CrR)was used to calculate the Delta change in renal function CrR-Cr3mo. The patients were then divided into 2 groups based on Qsant results of <32 (Q<32) or >32 (Q>32)

*Results: 21 patients were enrolled. 14 patients had been transplanted at least 1 year ago. The number of patients in the two groups were ; 8 Q<32 and 13 Q>32. The mean Qsant levels for Q<32 and Q>32 were 19.87(10-31) and 45.69 (33-83) respectively. The mean Cr3mo, CrR, delta change for Q<32 was 1.2 (0.81-2.21) mg/dl, 1.46(0.73-3.25)mg/dl , 0.25 ( -0.28 to 1.83) respectively and the mean Cr3mo, CrR, delta change for Q>32 was 1.69mg/dl (0.83-4.53) 1.55 mg/dl (0.92 -2.98), -0.14 (-2.38 to 0.55) respectively.

*Conclusions: In this preliminary analysis of a small observational study, the baseline renal function appeared better for the lower Qsant group. However, no significant difference in renal function from the baseline was apparent when a score of 32 was used as a cutoff between the groups. Additional values at different timepoints, and biopsy data is being collected prospectively to validate and corelate the findings of the novel urinary biomarker to the clinical observations.

« Back to 2022 American Transplant Congress